Search bioRxiv⌕ Search

Biology subjects

Iida, N.

Publications and source records attributed to Iida, N..

4 recordsLinked to original sources

Catalog of gut microbiota alterations associated with anticancer therapies across multiple cancer types

BackgroundAnticancer therapies can alter the gut microbiota and may affect gut bacteria associated with treatment response. However, most longitudinal studies have focused on specific cancer types or individual treatment regimens, and systematic analyses across diverse cancer therapies remain limited. We analyzed longitudinal fecal microbiota profiles using 16S ribosomal RNA gene amplicon sequencing in the pan-cancer SCRUM-Japan MONSTAR-SCREEN cohort. We included 528 paired pre- and post-treatment fecal samples from 264 patients with advanced solid tumors across 18 cancer types and characterized the gut microbiota alterations associated with 22 anticancer drugs and related clinical factors. ResultsAcross the cohort, Shannon diversity did not significantly change after treatment (mean, 3.81 vs. 3.78; P = 0.58), and pre- and post-treatment samples exhibited no clear separation in ordination space. However, within-patient analysis detected a subtle but significant longitudinal microbiota shift (paired PERMANOVA, P = 0.0001), highlighting the importance of accounting for paired sampling. Clustering of genus-level compositional alterations revealed patient groups with distinct degrees of microbiota alteration, with the largest shifts associated with antibiotic exposure, transition from normal stool to diarrhea, and specific treatment regimens. Multivariable regression analysis of 22 anticancer drugs identified drug-bacteria associations and demonstrated that drugs with similar mechanisms of action, including epidermal growth factor receptor (EGFR) inhibitors and immune checkpoint inhibitors, exhibited similar microbiota change profiles. Targeted analyses highlighted concordant reductions in the Christensenellaceae R-7 group among EGFR inhibitor-exposed patients and depletion of Faecalibacterium among immune checkpoint inhibitor-exposed patients. ConclusionsThis study provides a cross-cancer catalog of microbiota alterations associated with anticancer therapies and highlights therapy-related shifts in the gut ecosystem, including patterns shared by drugs with similar mechanisms of action.

microbiology↗

Systematically developing a registry of splice-site creating variants utilizing massive publicly available transcriptome sequence data

Genomic variants causing abnormal splicing play an important role in genetic disorders and cancer development. Among them, variants that cause formations of novel splice-sites (splice-site creating variants, SSCVs) are particularly difficult to identify and often overlooked in genomic studies. Additionally, these SSCVs, especially those found in deep intronic regions, are frequently considered promising candidates for treatment with splice-switching antisense oligonucleotides (ASOs), offering therapeutic potential for rare disease patients. To leverage massive transcriptome sequence data such as those available from the Sequence Read Archive, we developed a novel framework to screen for SSCVs solely using transcriptome data. We have applied it to 322,072 publicly available transcriptomes and identified 30,130 SSCVs. Utilizing this extensive collection of SSCVs, we have revealed the characteristics of Alu exonization via SSCVs, especially the hotspots of SSCVs within Alu sequences and their evolutionary relationships. Many of the SSCVs affecting disease-causing variants were predicted to generate premature termination codons and are degraded by nonsense-mediated decay. On the other hand, several genes, such as CREBBP and TP53, showed characteristic SSCV profiles indicative of heterogeneous mutational functions beyond simple loss-of-function. Finally, we discovered novel gain-of-function SSCVs in the deep intronic region of the NOTCH1 gene and demonstrated that their activation can be suppressed using splice-switching ASOs. Collectively, we provide a systematic approach for automatically acquiring a registry of SSCVs, which can be used for elucidating novel biological mechanisms for splicing and genetic variation, and become a valuable resource for pinpointing critical targets in drug discovery. Catalogs of SSCVs identified in this study are accessible on SSCV DB (https://sscvdb.io/).

bioinformatics↗

Impact of High Fat Diet and Sex in a Rabbit Model of Carpal Tunnel Syndrome

Carpal tunnel syndrome (CTS) is a common musculoskeletal disorder, characterized by thickening and fibrosis of the subsynovial connective tissue (SSCT). Risk factors for CTS includes sex, metabolic dysfunction and age. In this study we hypothesized that a high-fat diet (HFD), a common driver of metabolic dysfunction, would promote SSCT thickening in CTS and that this response would be sex dependent. To test this, we examined the effects of HFD and sex on SSCT thickening and markers of fibrosis using our established CTS rabbit model of SSCT thickening. Forty-eight (24 male, 24 female) adult rabbits were split into four groups including HFD or standard diet with and without CTS induction. SSCT was collected for histological and gene expression analysis. HFD promoted SSCT thickening and upregulated profibrotic genes, including TGF-{beta}. Fibrotic genes were differentially expressed in males and females. Interestingly while the overall prevalence of CTS is greater in women than in men, under conditions of metabolic dysfunction men have a higher incidence. This suggests a focus on metabolic and sex specific therapeutic strategies for the treatment of patients with CTS.

physiology↗

Systematic identification of intron retention associated variants from massive publicly available transcriptome sequencing data

Many disease-associated genomic variants disrupt gene function through abnormal splicing. With the advancement of genomic medicine, identifying disease-associated splicing associated variants has become more important than ever. Most bioinformatics approaches to detect splicing associated variants require both genome and transcriptomic data. However, there are not many datasets where both of them are available. In this study, we developed a methodology to detect genomic variants that cause splicing changes (more specifically, intron retention), using transcriptome sequencing data alone. After demonstrating its high sensitivity and precision, we have applied it to 230,988 transcriptome sequencing data from the publicly available repository and identified 27,937 intron retention associated variants (IRAVs). In addition, by exploring positional relationships with variants registered in existing disease databases, we extracted 3,077 putative disease-associated IRAVs, which range from cancer drivers to variants linked with autosomal recessive disorders. The new in-silico screening framework proposed here provides a foundation for a platform that can automatically acquire medical knowledge making the most of massively accumulated publicly available sequencing data. Collections of IRAVs identified in this study are available through IRAVDB (https://iravdb.io/).

bioinformatics↗